The compliance process at pharmaceutical manufacturers is a complicated and prone to errors because many still use paper-based systems to record manufacturing steps. These paper records are reviewed by FDA auditors to ensure that guidelines were followed, but they are prone to errors, often leading to warnings. This results in higher costs and slower manufacturing. Leucine wants to make the compliance process more efficient with its compliance cloud platform for the pharmaceutical industry. It automatically creates digital manufacturing records and uses AI to identify the root cause of deviations.New York-based Leucine announced today it has raised a $7 million Series A led by strategic investor Ecolab Inc. Participants include returning investors like Pravega Ventures, Axilor Ventures, Techstars and angel investors

New York-based start-up, Leucine, after securing a $7 million Series A funding led by Ecolab Inc., has unveiled its compliance cloud platform specifically tailored for the pharma sector.